LIMA1 Gene Knockout by CRISPR/Cas9 System Using Lentiviruses as an in Vitro Model for Reducing Cholesterol Absorption
| Author | Mahdieh Talebzadeh | en |
| Author | Vahid Razban | en |
| Author | Mahintaj Dara | en |
| Author | Hossein Jafari Khamirani | en |
| Author | Maryam Ranjbar | en |
| Author | Marjan Nourigorji | en |
| Author | Farid Torabizadeh | en |
| Author | Mehdi Dianatpour | en |
| Orcid | Mahdieh Talebzadeh [0000-0002-7898-632X] | en |
| Orcid | Vahid Razban [0000-0002-8966-6081] | en |
| Orcid | Mahintaj Dara [0000-0003-0087-3162] | en |
| Orcid | Hossein Jafari Khamirani [0000-0001-7703-7387] | en |
| Orcid | Maryam Ranjbar [0000-0001-5148-8921] | en |
| Orcid | Marjan Nourigorji [0000-0001-6121-983X] | en |
| Orcid | Mehdi Dianatpour [0000-0003-1217-9477] | en |
| Issued Date | 2022-12-31 | en |
| Abstract | Background: Cardiovascular diseases, with an estimated 18.6 million deaths per year, are the leading cause of death worldwide. One of the major risk factors is elevated blood low-density lipoprotein cholesterol (LDL-C) secondary to multiple environmental and genetic factors. Genes involved in LDL-C metabolism are the targets of the most common treatment options. Advanced molecular techniques could pave the way for identifying novel targets in dyslipidemia therapies. The LIM domain and actin-binding 1 (LIMA1) gene binds to the NPC1L1 protein and facilitates its more efficient recycling to the plasma membrane. Inhibition of LIMA1 could disrupt cellular cholesterol hemostasis with a probable decrease in blood LDL-C levels. | en |
| DOI | https://doi.org/ | en |
| Keyword | CRISPR/Cas9 | en |
| Keyword | Cardiovascular diseases | en |
| Keyword | EPLIN | en |
| Keyword | Cholesterol | en |
| Keyword | LIMA1 | en |
| Publisher | Brieflands | en |
| Title | LIMA1 Gene Knockout by CRISPR/Cas9 System Using Lentiviruses as an in Vitro Model for Reducing Cholesterol Absorption | en |
| Type | Research Article | en |